|By Business Wire||
|December 3, 2013 01:45 AM EST||
MEDIAN Technologies (Paris:ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, today announced it has signed a three-year collaborative agreement with South Texas Accelerated Research Therapeutics (START). With centers located in San Antonio, Texas, and Madrid, Spain, START conducts the world’s largest Phase I medical oncology program, putting more than 400 patients per year in Phase I trials. The mission of START is to accelerate the development of new anticancer drugs that will improve the quality of life and survival for patients.
Today, medical images are instrumental in evaluating whether a patient responds or not to therapy. According to the terms of the agreement, MEDIAN’s LMS software application will be used for image interpretation and management during Phase I oncology trials conducted by START. The objective is to provide START with best-in-class imaging tools to better assess patient response to therapy based on the implementation of standard imaging criteria, such as RECIST1, and advanced imaging biomarkers, such as tumor volume. In the growing area of oncology drug research, advanced imaging biomarkers provide early efficacy indications and support data-driven Go/No Go decision making, which is of critical importance.
‘We are very proud and enthusiastic about the agreement we have signed with START,” said Fredrik Brag, Chairman and Chief Executive Officer of MEDIAN Technologies. “START’s reputation for excellence and innovation through technology make them an ideal partner for us. We believe that our LMS application provides immense value for better assessing oncology patients’ response to therapy in clinical trials. The addition of our LMS applications to START’s current capabilities will bring tremendous combined value to the Phase I setting. Having accurate quantitative information from images helps sponsors make the right decisions regarding the pursuit of research on a given molecule, which ultimately benefits patients.” he added.
“START also is proud to have signed this agreement, and to be working with MEDIAN Technologies,” said Dr. Anthony Tolcher, Director of Clinical Research for START. “This innovative imaging technology nicely complements our web-based real-time delivery of clinical trial data and will assist our clinical trial sponsors to objectively verify responses in real-time and, we believe, help many of them identify opportunities for breakthrough designation. Imaging has a growing significance in phase I oncology trials, so adding LMS to our arsenal of innovative tools will provide sponsors with valuable data that will support not only the early phase decision making, but also help lay the groundwork for follow-on, late phase trials.” Dr. Tolcher added.
About MEDIAN Technologies: please visit: www.mediantechnologies.com
1 RECIST : Response Evaluation Criteria in Solid Tumors – Introduced in 2000 by an International Working Party to standardize & simplify tumor response criteria in oncology trials, RECIST is widely accepted as a standardized measure of tumor response. RECIST criteria has been revised in 2010 (RECIST 1.1. version)